SG11201703135XA - Methods of treating ocular conditions - Google Patents
Methods of treating ocular conditionsInfo
- Publication number
- SG11201703135XA SG11201703135XA SG11201703135XA SG11201703135XA SG11201703135XA SG 11201703135X A SG11201703135X A SG 11201703135XA SG 11201703135X A SG11201703135X A SG 11201703135XA SG 11201703135X A SG11201703135X A SG 11201703135XA SG 11201703135X A SG11201703135X A SG 11201703135XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating ocular
- ocular conditions
- conditions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US201562100844P | 2015-01-07 | 2015-01-07 | |
| PCT/US2015/056273 WO2016064759A1 (en) | 2014-10-20 | 2015-10-19 | Methods of treating ocular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703135XA true SG11201703135XA (en) | 2017-05-30 |
Family
ID=55748136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011669PA SG10202011669PA (en) | 2014-10-20 | 2015-10-19 | Methods of treating ocular conditions |
| SG11201703135XA SG11201703135XA (en) | 2014-10-20 | 2015-10-19 | Methods of treating ocular conditions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011669PA SG10202011669PA (en) | 2014-10-20 | 2015-10-19 | Methods of treating ocular conditions |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US9532944B2 (en) |
| EP (2) | EP3209295B2 (en) |
| JP (3) | JP6873906B2 (en) |
| KR (2) | KR102601505B1 (en) |
| CN (3) | CN107106542B (en) |
| AU (2) | AU2015336216B2 (en) |
| BR (2) | BR122022025737B1 (en) |
| CA (1) | CA2965129C (en) |
| DK (1) | DK3209295T4 (en) |
| EA (1) | EA035335B1 (en) |
| ES (1) | ES2848977T3 (en) |
| IL (2) | IL251769B (en) |
| MX (2) | MX2017005064A (en) |
| MY (1) | MY186870A (en) |
| PH (1) | PH12017500602A1 (en) |
| PT (1) | PT3209295T (en) |
| SG (2) | SG10202011669PA (en) |
| WO (1) | WO2016064759A1 (en) |
| ZA (1) | ZA201703467B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9532944B2 (en) | 2014-10-20 | 2017-01-03 | Oyster Point Pharma, Inc. | Methods of improving ocular discomfort |
| JP7090551B2 (en) * | 2016-04-07 | 2022-06-24 | オイスター ポイント ファーマ インコーポレイテッド | How to treat eye conditions |
| WO2020014232A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| TW202019424A (en) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | Methods of treating ocular conditions |
| TW202206078A (en) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| CA2468705A1 (en) | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| MX2007004495A (en) | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline. |
| CA2586074C (en) * | 2004-11-09 | 2013-07-23 | Novagali Pharma Sa | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| WO2006100075A2 (en) * | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| JP5276982B2 (en) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Method for the treatment of headache by administration of oxytocin |
| US8182841B2 (en) | 2005-09-27 | 2012-05-22 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-inflammation methods |
| TWI404532B (en) | 2006-11-02 | 2013-08-11 | Targacept Inc | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes |
| DK2114970T3 (en) * | 2007-02-02 | 2011-09-19 | Pfizer Prod Inc | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (en) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| RU2010140613A (en) | 2008-03-05 | 2012-04-10 | Таргасепт, Инк. (Us) | AMIDES OF DIAZABicycloalkanes Selective for the Subtype of Nicotinic Acetylcholine Receptors |
| JP2012502039A (en) * | 2008-09-05 | 2012-01-26 | ターガセプト，インコーポレイテッド | Diazabicyclooctane amides and uses thereof |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| PT3279195T (en) | 2008-12-01 | 2020-09-29 | Oyster Point Pharma Inc | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| US20140128606A1 (en) * | 2011-06-30 | 2014-05-08 | Toray Industries, Inc. | Antipruritic agent |
| JP6162705B2 (en) * | 2011-10-20 | 2017-07-12 | ノバルティス アーゲー | Biomarkers predicting responsiveness to treatment with alpha 7 nicotinic acetylcholine receptor activators |
| EP3029463A1 (en) * | 2011-11-30 | 2016-06-08 | DiagnosTear Ltd | Dry eye diagnostic |
| US9682032B2 (en) | 2013-03-15 | 2017-06-20 | Glia, Llc | Cranial delivery of pharmaceuticals |
| US8996137B2 (en) | 2013-04-19 | 2015-03-31 | Oculeve, Inc. | Nasal stimulation devices and methods |
| US9532944B2 (en) | 2014-10-20 | 2017-01-03 | Oyster Point Pharma, Inc. | Methods of improving ocular discomfort |
| JP7090551B2 (en) | 2016-04-07 | 2022-06-24 | オイスター ポイント ファーマ インコーポレイテッド | How to treat eye conditions |
| TW202019424A (en) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | Methods of treating ocular conditions |
| WO2020014232A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
-
2015
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 EA EA201790893A patent/EA035335B1/en unknown
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/en active IP Right Grant
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en active Application Filing
- 2015-10-19 PT PT158523407T patent/PT3209295T/en unknown
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/en active Active
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/en active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 ES ES15852340T patent/ES2848977T3/en active Active
- 2015-10-19 CN CN202010304375.2A patent/CN111956803A/en active Pending
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/en active Application Filing
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/en active IP Right Grant
- 2015-10-19 CN CN202010304809.9A patent/CN111956650A/en active Pending
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/en active IP Right Grant
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/en active Active
- 2015-10-19 MX MX2017005064A patent/MX2017005064A/en unknown
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 IL IL293188A patent/IL293188A/en unknown
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 EP EP20212556.3A patent/EP3848028A1/en active Pending
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/en unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/en active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP2023024574A/en active Pending
-
2023
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283561B (en) | Methods for treating ocular diseases | |
| GB201701673D0 (en) | Methods of well treatment | |
| HK1246179A1 (en) | Methods of treating retinal diseases | |
| IL257252B1 (en) | Methods of treating fgf21-associated disorders | |
| IL246791A0 (en) | Compositions and methods for treating ocular diseases | |
| HK1248552A1 (en) | Method of treatment with tradipitant | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| IL290069A (en) | Methods of treating ocular conditions | |
| GB201410116D0 (en) | Method of treatment | |
| IL251769A0 (en) | Methods of treating ocular conditions | |
| GB201416832D0 (en) | Methods of treatment | |
| HK1244692A1 (en) | Methods of treating fibrosis | |
| IL253028A0 (en) | Method of treatment | |
| HK1249866A1 (en) | Methods of treatment with taselisib | |
| HK1243937A1 (en) | Methods of treating diseases | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201421980D0 (en) | Method of treatment | |
| GB201421982D0 (en) | Method of treatment | |
| GB201415331D0 (en) | Method of treatment | |
| GB201414780D0 (en) | Method Of Treatment | |
| GB201511017D0 (en) | Method of treatment | |
| AU2014905194A0 (en) | Method of Treatment | |
| AU2014904907A0 (en) | Method of Treatment | |
| AU2014904371A0 (en) | Method of treatment |